Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

drugs.com - 26/Jun 19:06

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

NIH-Sponsored Trial of Enterovirus D68 Therapeutic Begins

drugs.com - 27/Jun 06:07

June 27, 2024 -- The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal...

Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

drugs.com - 05/Jul 00:07

Basel, 04 July 2024 - Roche announced today that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq (atezolizumab) and...

Genentech Provides Update on Phase II/III Skyscraper-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer

drugs.com - 03/Jul 06:07

South San Francisco, CA -- July 3, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III...

Rocket Pharmaceuticals Provides Regulatory Update on Kresladi (marnetegragene autotemcel; marne-cel)

drugs.com - 28/Jun 05:07

CRANBURY, N.J.--(BUSINESS WIRE)--Jun. 28, 2024-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company...

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY

zacks.com - 04/Jul 17:49

Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of...

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

financialpost.com - 23/Jun 16:08

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161...

Another Feather In The Cap Of Treatment As HIV Prevention – OpEd

eurasiareview.com - 22/Jun 22:50

Results of a phase 3 PURPOSE 1 HIV prevention study done among adolescent girls and young women in South Africa and Uganda show that there were no...

Promising results from the Phase 2 study of novel extended-release ketamine tablets (R-107) for Treatment-Resistant Depression accepted for publication by Nature Medicine

drugs.com - 24/Jun 23:06

AUCKLAND, New Zealand, June 24, 2024. Douglas Pharmaceuticals, New Zealand's largest pharmaceutical company, is pleased to announce that results from...

Walking and education intervention significantly reduces recurrence of low back pain

news.medical.net - 24/Jun 13:50

Researchers conducted a randomized controlled trial to determine the clinical efficacy and cost-efficiency of the WalkBack personalized, walking, and...

Rubriques :